.png){kind=icon}
.png){kind=icon}
Return
The relationship between SGLT2 inhibitors and hearing loss: a nationwide population-based retrospective cohort study
.png){kind=icon}
OA
AI
C
Y
C
L
W
H
C
D
K
DOI：10.1186/s13098-025-02026-7.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Sensorineural hearing loss (SNHL) is a common but underrecognized complication of type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) use was associated with favorable renal and cardiovascular outcomes beyond glycemic control, but their impact on auditory outcomes remains unclear. We conducted a nationwide cohort study using Taiwan’s National Health Insurance Research Database (2000–2021). Patients with T2DM who received SGLT2i for ≥ 90 days were compared with matched non-users. Propensity score matching was applied 1:1 based on demographic, clinical, and treatment characteristics. The primary outcome was the incidence of SNHL, confirmed by audiometric testing. A total of 381,592 patients with type 2 diabetes mellitus (T2DM) were included. Compared with non-users, SGLT2i users exhibited a significantly lower risk of SNHL (adjusted hazard ratios (aHRs) = 0.84; 95% CI: 0.75–0.94). Subgroup analyses confirmed a consistent lower risk across sex, age, urbanization, and comorbidity strata. Notably, long-term SGLT2i use (≥ 366 days) showed a strong dose–response association with reduced SNHL risk (aHR = 0.32; 95% CI: 0.27–0.39). SGLT2i use in T2DM patients is associated with a reduced risk of SNHL, particularly with sustained therapy. These findings highlight a potential association between SGLT2i use and a lower risk of auditory complications in diabetes, underscoring the importance of considering hearing health within comprehensive diabetes management.
Keywords:
Type 2 diabetes
SGLT2 inhibitor
Sensorineural hearing loss
Population-based study
Auditory outcomes
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.9
Papers:
2.3K
Citations:
5.7K
Organization
Cited Papers